Similar Posts
CASCAIDr CIC launched to provide advice on health and social care legal rights
CASCAIDr CIC (Centre for Adults’ Social Care – Analysis, Information and Dispute Resolution) has been launched to offer information and analysis relating to The Care Act, NHS CHC and issues about legal rights to care and support in England and Wales. CASCAIDr CIC offer four free services to anyone in the general public (age 16+)…
Participants wanted for survey on post-falls management in English care homes
Researchers at Nottingham University Hospitals (NUH) NHS Trust are looking for participants to complete their survey to map post-falls management processes and procedures in England. The survey is part of their study to develop principles for providing care immediately after an older person (aged 65+) falls in a care home. The survey is open to…
Carers UK launch ‘This Counts as Care’
Carers UK has launched a new campaign entitled ‘This Counts as Care’ to help those who don’t currently identify as an unpaid carer to see themselves in this way. Carers UK say: “There are currently 5.7 million unpaid carers in the UK caring for an ill, elderly or disabled relative or friend long-term, with 4.7%…
Young dementia
Young Dementia Network (YDN) has created a short animation explaining what YDN is, what it does and how to join up. The narrator in the “What is the Young Dementia Network” video, available on the YDN website and on its YouTube channel, talks from the perspective of someone with young onset dementia and the typical…
Potential treatment for Parkinson’s dementia
A potential drug treatment for Parkinson’s dementia called ENT-01 improved cognitive function in some trial participants. During the 10-week treatment period these participants had better mental abilities such as remembering and problem-solving, and these continued to improve during the six weeks following treatment. The charity Parkinson’s UK has invested £2 million in phase 2 of…
Drug licence refused
A decision by the European Medicines Agency (EMA) to refuse a licence for the dementia drug aducanumab has been described as “bitterly disappointing news for people with Alzheimer’s disease.” Alzheimer’s Research UK chief executive Hilary Evans made the comment after the EMA rejected an application by the manufacturer Biogen to distribute the drug across the…